Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Innoviva ( (INVA) ) has shared an update.
On May 12, 2026, Innoviva directors Derek Small and Mark DiPaolo resigned from the board to concentrate on expanding Syndeio BioSciences, where Small is chief executive and DiPaolo is set to take an executive role, with Innoviva signaling ongoing financial and strategic support for Syndeio’s neuropsychiatric drug programs. The company said the departures were not due to disagreements and, on May 18, 2026, appointed veteran investment executive and former Goldman Sachs partner Josephine Linden as an independent director, assigning her to the audit committee and granting her a mix of restricted stock units and stock options under Innoviva’s 2026 equity plan, reinforcing the board’s financial oversight and governance depth.
The most recent analyst rating on (INVA) stock is a Buy with a $42.00 price target. To see the full list of analyst forecasts on Innoviva stock, see the INVA Stock Forecast page.
Spark’s Take on INVA Stock
According to Spark, TipRanks’ AI Analyst, INVA is a Outperform.
The score is primarily supported by strong recent financial performance (high profitability, improved leverage, and positive cash generation) and a very low P/E valuation. These positives are tempered by weak/neutral technical momentum and notable historical volatility in profitability and free-cash-flow growth.
To see Spark’s full report on INVA stock, click here.
More about Innoviva
Innoviva, Inc. is a healthcare-focused company that invests in and supports biopharmaceutical ventures, including its portfolio company Syndeio BioSciences, which is developing therapies for neuropsychiatric and related disorders. The company derives revenues from partnered respiratory products and continues to pursue a broader growth strategy and corporate development initiatives in the life sciences sector.
Average Trading Volume: 708,031
Technical Sentiment Signal: Buy
Current Market Cap: $1.62B
Find detailed analytics on INVA stock on TipRanks’ Stock Analysis page.